CNTA - Centessa stock falls as company pulls plug on lixivaptan kidney disease program after liver issue in patient

Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both a phase 3 trial called ACTION and an open-label study, dubbed ALERT. ADPKD is a genetic disorder characterized by growth of cysts in the kidneys. The company said elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were recently seen in one patients in the ALERT study. ALT and AST are enzymes, high levels of these may indicate liver damage. The ALERT trial was aimed at evaluating the liver and non-liver safety of lixivaptan in patients with ADPKD who previously experienced liver chemistry abnormalities while treated with tolvaptan, which is sold as Samsca/Jynarque by Otsuka Pharmaceutical (OTCPK:OTSKF)(OTCPK:OTSKY), and were permanently discontinued from the drug for that reason, according to the company's June 2 release. Centessa added that decision was

For further details see:

Centessa stock falls as company pulls plug on lixivaptan kidney disease program after liver issue in patient